CSRxP spokesman Will Holley released the following statement applauding the Trump Administration’s focus on drug prices and the recent positive announcements from certain brand-name drug manufacturers:
“The recent announcements by companies like Pfizer, Novartis, Lilly, and Merck that they will take various positive steps on drug prices by cutting the price of certain drugs, limiting forthcoming price increases, or supporting procompetitive reforms like the CREATES Act are welcome news. The Trump Administration deserves real credit for its focus on out-of-control drug prices over the last 18 months.
“The real challenge is to enact long-lasting structural reforms that change the incentives that produce ever-increasing list and launch prices for prescription drugs. We applaud the Administration for its focus on out-of-control prescription drug prices and we look forward to working with policymakers in the Administration as well as Members of Congress on both sides of the aisle to achieve our shared goal of lower drug prices for all Americans.”